PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-304.29%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
27.06%
Positive operating income growth while TRVN is negative. John Neff might view this as a competitive edge in operations.
-304.05%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-302.06%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-288.66%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.11%
Share change of 0.11% while TRVN is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
3.68%
Diluted share change of 3.68% while TRVN is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
56.08%
Positive OCF growth while TRVN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
56.11%
Positive FCF growth while TRVN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18524.76%
Negative 10Y OCF/share CAGR while TRVN stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-17391.51%
Negative 5Y OCF/share CAGR while TRVN is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-1778.39%
Negative 3Y OCF/share CAGR while TRVN stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-42866.91%
Negative 10Y net income/share CAGR while TRVN is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-15208.07%
Negative 5Y net income/share CAGR while TRVN is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-5247.61%
Negative 3Y CAGR while TRVN is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
4590.00%
Equity/share CAGR of 4590.00% while TRVN is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
1682.71%
Equity/share CAGR of 1682.71% while TRVN is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
1405.22%
Equity/share CAGR of 1405.22% while TRVN is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Asset growth of 70.82% while TRVN is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
247.25%
BV/share growth of 247.25% while TRVN is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
-50.51%
We’re deleveraging while TRVN stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-53.09%
Our R&D shrinks while TRVN invests at 65.23%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.56%
SG&A declining or stable vs. TRVN's 14.43%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.